AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
FRA Edition 
GER Edition 
ESP Edition 
ITA Edition 
NLD Edition 
PRT Edition 
SWE Edition 
GRC Edition 
IND Edition 
POL Edition 
BRA Edition 
ZAF Edition 
RUS Edition 
CHN Edition 
UAE Edition 
⚠
✓
MiMedx Group Inc (NASDAQ:MDXG)
6.03 USD
+0.070 1.175%Sponsored Reports
Loading...
| Previous Close (in USD) | 5.96 |
|---|---|
| Change | +0.070 1.175% |
| 52 W H/L (in USD) | 9.270/5.470 |
| EBITDA (in USD) | 53.978M |
| PE Ratio | 15.02 |
| Volume | 182972 |
| Diluted Eps TTM | 0.50 |
| Total Assets (in USD) | 239.047M |
|---|---|
| Total Liabilities (in USD) | 96.33M |
| Revenue TTM (in USD) | 334.51M |
| Cash (in USD) | 82M |
| Market Cap (in USD) | 1,108.506 M |
| Revenue Per Share TTM | 2.687 |
| Gross Profit TTM (in USD) | 219.525M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Dividend Paid
MiMedx Group Inc
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a barrier membrane allograft used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; and EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications. The company's products have applications in the areas of wound care, burn, surgical sectors of healthcare. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. was incorporated in 2011 and is headquartered in Marietta, Georgia.
1775 West Oak Commons Court, NE, Marietta, GA, United States, 30062
770 651 9100
Employees: 895
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Mr. K. Todd Newton | Interim CEO & Director | 1963 |
| 2. | Mr. Peter Martin Carlson CPA | Chief Financial Officer | 1964 |
| 3. | Mr. William F. Hulse IV | Gen. Counsel & Chief Admin. Officer | 1974 |
| 4. | Dr. Rohit Kashyap Ph.D. | Pres of Wound Care & Surgical | 1971 |
| 5. | Dr. Robert Benjamin Stein M.D., Ph.D. | Pres of Regenerative Medicine & Biologics Innovation | 1951 |
| 6. | Mr. Scott M. Turner | Sr. VP of Operations & Procurement | 1965 |
| 7. | Mr. William L. Phelan | Sr. VP & Chief Accounting Officer | NA |
| 8. | Mr. Matthew M. Notarianni | Head of Investor Relations | NA |
| 9. | Mr. Mark P. Graves | Sr. VP & Chief Compliance Officer | 1966 |
| 10. | Hilary Dixon | VP of Investor Relations & Corp. Strategic Communications | NA |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
-3.600 5.090% | 68.86 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
-2.680 3.811% | 68.6 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
-5.190 1.153% | 450.48 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
-0.570 0.109% | 521.4 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Income Before Tax | -29.991M | -10.038M | -25.585M | -3.397M | -3.397M |
| Minority Interest | - | - | - | - | - |
| Net Income | -30.197M | -10.285M | -25.58M | -29.979M | -29.979M |
| Selling General Administrative | 208.789M | 198.359M | 181.022M | 252.628M | 252.628M |
| Gross Profit | 219.525M | 215.332M | 256.174M | 322.725M | 322.725M |
| Reconciled Depreciation | 4.046M | 5.183M | 6.855M | 7.585M | 6.916M |
| Ebit | -24.971M | -5.005M | -20.714M | -3.924M | -3.924M |
| Ebitda | -20.929M | 0.178M | -12.683M | 2.992M | 2.992M |
| Depreciation And Amortization | 4.042M | 5.183M | 8.031M | 6.916M | 6.916M |
| Operating Income | -24.971M | -5.005M | -20.714M | -3.924M | -3.924M |
| Other Operating Expenses | 292.812M | 263.597M | 319.969M | 363.035M | 363.035M |
| Interest Expense | 5.016M | 4.98M | -4.708M | 0M | 0M |
| Tax Provision | 0.206M | 0.247M | -12.259M | -0.005M | 26.582M |
| Interest Income | - | - | - | - | - |
| Net Interest Income | -5.016M | -4.98M | -7.941M | -4.708M | - |
| Income Tax Expense | 0.206M | 0.247M | -0.005M | 26.582M | 26.582M |
| Total Revenue | 267.841M | 258.615M | 299.255M | 359.111M | 359.111M |
| Total Operating Expenses | 244.496M | 220.314M | 276.888M | 326.649M | 326.649M |
| Cost Of Revenue | 48.316M | 43.283M | 43.081M | 36.386M | 36.386M |
| Total Other Income Expense Net | -5.02M | -5.033M | -4.871M | 0.527M | 0.527M |
| Net Income From Continuing Ops | -30.197M | -10.285M | -49.284M | -25.58M | -29.979M |
| Net Income Applicable To Common Shares | -36.777M | -10.285M | -83.328M | -25.58M | -29.979M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 239.047M | 171.43M | 187.929M | 167.166M | 122.844M |
| Intangible Assets | 5.257M | 5.852M | 5.383M | 7.777M | 9.608M |
| Other Current Assets | 1.745M | 2.631M | 2.809M | 6.058M | 5.818M |
| Total Liab | 96.33M | 189.418M | 187.847M | 132.768M | 73.189M |
| Total Stockholder Equity | 142.717M | -17.988M | 0.082M | 34.398M | 49.655M |
| Other Current Liab | 36.96M | 34.71M | 34.972M | 1.399M | 56.683M |
| Common Stock | 0.146M | 0.114M | 0.113M | 0.113M | 0.113M |
| Capital Stock | 0.146M | 0.114M | 92.607M | 91.681M | 0.113M |
| Retained Earnings | -133.678M | -17.988M | -161.709M | -102.14M | -76.56M |
| Good Will | 19.441M | 19.976M | 19.976M | 19.976M | 19.976M |
| Other Assets | - | 0.148M | 0.186M | 0.375M | 0.443M |
| Cash | 82M | 65.95M | 87.083M | 69.069M | 45.118M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 46.008M | 43.557M | 42.357M | 67.322M | 71.547M |
| Current Deferred Revenue | -1.548M | - | - | 53.463M | - |
| Net Debt | -33.901M | -17.356M | -38.956M | -3.413M | -45.118M |
| Short Term Debt | 1.548M | - | - | 3.75M | 3.75M |
| Short Long Term Debt | - | - | - | - | 3.75M |
| Short Long Term Debt Total | 48.099M | 48.594M | 48.127M | 65.656M | 65.656M |
| Other Stockholder Equity | 276.249M | -92.608M | 161.678M | 136.425M | 144.689M |
| Property Plant Equipment | - | 11.256M | 13.861M | 11.437M | 15.725M |
| Total Current Assets | 164.261M | 134.198M | 148.523M | 123.245M | 74.049M |
| Long Term Investments | - | - | - | - | - |
| Short Term Investments | - | - | - | - | - |
| Net Receivables | 53.871M | 43.788M | 41.096M | 32.345M | 0.454M |
| Long Term Debt | 48.099M | 48.594M | 48.127M | 47.697M | 61.906M |
| Inventory | 21.021M | 13.183M | 11.389M | 9.104M | 15.986M |
| Accounts Payable | 9.048M | 8.847M | 7.385M | 8.71M | 14.864M |
| Accumulated Other Comprehensive Income | -239.047M | - | -92.494M | -91.568M | -18.587M |
| Non Currrent Assets Other | 0.205M | 0.148M | 0.186M | 0.443M | 1.787M |
| Non Current Assets Total | 74.786M | 37.232M | 39.406M | 43.921M | 48.795M |
| Capital Lease Obligations | - | - | - | - | - |
| Long Term Debt Total | - | - | - | - | 61.906M |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Investments | -2.66M | -3.395M | -4.555M | 2.722M | 0.778M |
| Total Cashflows From Investing Activities | -2.66M | -3.395M | -4.555M | 0.504M | -9.22M |
| Total Cash From Financing Activities | -0.58M | -3.352M | 62.859M | -8.934M | -8.934M |
| Net Income | -30.197M | -10.285M | -25.58M | -29.979M | -29.979M |
| Change In Cash | -21.133M | -8.729M | 23.951M | 17.642M | 17.642M |
| Begin Period Cash Flow | 87.083M | 95.812M | 45.118M | 27.476M | 27.476M |
| End Period Cash Flow | 65.95M | 87.083M | 69.069M | 45.118M | 45.118M |
| Total Cash From Operating Activities | -17.893M | -1.982M | -39.412M | 35.796M | 35.796M |
| Depreciation | 4.046M | 5.183M | 7.585M | 6.916M | 6.916M |
| Other Cashflows From Investing Activities | - | 0.075M | -0.327M | -0.466M | -0.579M |
| Dividends Paid | -0.651M | - | -100M | - | - |
| Change To Inventory | -1.794M | -1.028M | 6.882M | -6.519M | -6.519M |
| Sale Purchase Of Stock | -1.19M | -4.751M | -1.474M | -12.486M | -4.017M |
| Other Cashflows From Financing Activities | 0.651M | 1.437M | 66.208M | 3.555M | 36.166M |
| Capital Expenditures | 2.684M | 3.47M | 2.218M | 10.028M | 9.419M |
| Change In Working Capital | -9.029M | -14.077M | -20.053M | 18.603M | -0.435M |
| Other Non Cash Items | 4.621M | 2.125M | -15.004M | -0.053M | 14.715M |
| Free Cash Flow | -20.577M | -5.452M | -41.63M | 25.768M | 25.768M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Vanguard Total Stock Mkt Idx Inv | 1 year ago | 2742933 |
| 2. | iShares Russell 2000 ETF | 1 year ago | 2676284 |
| 3. | SPDR® S&P Biotech ETF | 1 year ago | 2238198 |
| 4. | Vanguard Institutional Extnd Mkt Idx Tr | 1 year ago | 1754779 |
| 5. | Fidelity Small Cap Index | 1 year ago | 1179529 |
| 6. | iShares Russell 2000 Value ETF | 1 year ago | 1066300 |
| 7. | State St Russell Sm/Mid Cp® Indx NL Cl C | 1 year ago | 713048 |
| 8. | Fidelity Extended Market Index | 1 year ago | 668246 |
| 9. | Royce Small-Cap Opportunity Invmt | 1 year ago | 552578 |
| 10. | Schwab US Small-Cap ETF™ | 1 year ago | 545259 |
| 11. | Paradigm Micro-Cap | 1 year ago | 500000 |
| 12. | Federated Hermes MDT Small Cap Core IS | 1 year ago | 467175 |
| 13. | Federated Hermes MDT SCC Institutional | 1 year ago | 467175 |
| 14. | Vanguard Russell 2000 ETF | 1 year ago | 434611 |
| 15. | RBC U.S. Small-Cap Core Equity Fund F | 1 year ago | 425250 |
| 16. | Invesco Dorsey Wright SmallCap Momt ETF | 1 year ago | 422597 |
| 17. | State St Russell Sm Cap® Indx SL Cl I | 1 year ago | 416144 |
| 18. | Xtrackers S&P Global Infra Swap ETF 1C | 1 year ago | 410975 |
| 19. | Vanguard Health Care ETF | 1 year ago | 399041 |
| 20. | Federated Hermes MDT Small Cap Growth IS | 1 year ago | 393046 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Essex Woodlands Health Ventures | 1 year ago | 28195249 |
| 2. | BlackRock Inc | 1 year ago | 9533518 |
| 3. | Vanguard Group Inc | 1 year ago | 5922724 |
| 4. | State Street Corporation | 1 year ago | 4088962 |
| 5. | Paradigm Capital Management, Inc. | 1 year ago | 3908500 |
| 6. | Trigran Investments Inc | 1 year ago | 3256949 |
| 7. | Geode Capital Management, LLC | 1 year ago | 2538182 |
| 8. | Cannell Capital LLC | 1 year ago | 2433494 |
| 9. | Morgan Stanley - Brokerage Accounts | 1 year ago | 1587593 |
| 10. | Renaissance Technologies Corp | 1 year ago | 1251785 |
| 11. | Charles Schwab Investment Management Inc | 1 year ago | 1171413 |
| 12. | Richmond Brothers Inc | 1 year ago | 1097016 |
| 13. | Royal Bank of Canada | 1 year ago | 1079097 |
| 14. | Northern Trust Corp | 1 year ago | 1076586 |
| 15. | Prudential Financial Inc | 1 year ago | 1035760 |
| 16. | Goldman Sachs Group Inc | 1 year ago | 970474 |
| 17. | Arrowstreet Capital Limited Partnership | 1 year ago | 930149 |
| 18. | Federated Hermes Inc | 1 year ago | 911364 |
| 19. | Royce & Associates, LP | 1 year ago | 896616 |
| 20. | Dimensional Fund Advisors, Inc. | 1 year ago | 879379 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...